Article Text
PDF
Statistics from Altmetric.com
Q In patients with asthma receiving budesonide-formoterol (B-F) for maintenance treatment, how does B-F as needed reliever treatment compare with as needed formoterol and as needed terbutaline for reducing exacerbations?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Paediatrics ★★★★★★☆ Respirology ★★★★★☆☆
METHODS
Design:
randomised controlled trial.
Allocation:
concealed.*
Blinding:
blinded (patients and healthcare providers).*
Follow up period:
12 months.
Setting:
289 centres in 20 countries.
Patients:
3394 patients ⩾12 years of age (mean age 42 y, 60% women) who had >1 severe asthma exacerbation in the past 12 months, had used inhaled corticosteroids (ICS) for ⩾3 months, and had an FEV1 of 50–100% of predicted normal with ⩾12% reversibility after inhalation of terbutaline, 1 mg. Exclusion criteria included respiratory infection affecting asthma and use of oral corticosteroids within 1 month of study …
Footnotes
-
↵* See glossary.
-
For correspondence: Professor K F Rabe Leiden University Medical Centre, Leiden, The Netherlands. K.F.Rabe{at}lumc.nl
-
Source of funding: AstraZeneca.